交易 Kyowa Kirin Co., Ltd. - 4151 差价合约

交易条件

• 类型该金融市场可进行差价合约交易。了解更多:差价合约: 差价合约
• 点差: 4.9
• 长仓隔夜仓息调整长仓隔夜仓息调整保证金。您的投资¥1,000隔夜仓息来自头寸全值的费用-0.014438 %(-¥3)使用杠杆的交易规模（大约值）¥20,000来自杠杆的资金 - 美元（大约值）¥19,000前往平台: -0.01444%
• 短仓隔夜仓息调整短仓隔夜仓息调整保证金。您的投资¥1,000隔夜仓息来自头寸全值的费用-0.007784 %(-¥2)使用杠杆的交易规模（大约值）¥20,000来自杠杆的资金 - 美元（大约值）¥19,000前往平台: -0.00778%
• 隔夜调整仓息时间: 21:00 (UTC)
• 货币: JPY
• 最低成交量: 1
• 保证金: 5.00%
• 证券交易所: Japan
• 交易佣金: 0%
• 保证止损溢价保证止损 (GSL) 费用仅在 GSL 被触发时收取。更多详情请参阅我们网站的“服务费用”页面。: 1%

• 保证金。您的投资: ¥1,000
• 隔夜仓息来自头寸全值的费用: -0.014438 %
  (-¥3)

• 保证金。您的投资: ¥1,000
• 隔夜仓息来自头寸全值的费用: -0.007784 %
  (-¥2)

主要统计数据

• 前收盘价: 2261.3
• 开仓: 2238.9
• 1 年变化: -26.55%
• 日区间: 2238.4 - 2264.6

交易 Kyowa Kirin Co., Ltd. - 4151

Kyowa Kirin Co., Ltd., a specialty pharmaceutical company, manufactures and markets pharmaceuticals focused on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; GRAN, a human colony-stimulating factor; and G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia. The company's products also comprise LEUNASE for acute lymphoblastic leukemia; Mitomycin-C, an anticancer antibiotic; Moventig, an oral once daily peripherally acting mu-opioid receptor antagonist for the treatment of opioid induced constipation in adult patients; PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody that targets CC chemokine receptor 4; and REGPARA, an agent for the treatment of secondary hyperparathyroidism. In addition, it offers Romiplate/Nplate, a genetically recombinant protein, which stimulates platelet production through the stimulation of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.